Tailored antifungal dosing aims to protect elderly patients
NCT ID NCT07496008
First seen Mar 29, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This study focuses on older adults (over 60) with serious fungal infections like invasive aspergillosis. Researchers want to see if adjusting the dose of the antifungal drug isavuconazole based on individual patient factors can improve treatment outcomes and reduce side effects. The goal is to find the safest and most effective dose for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISAVUCONAZOLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.